Exhaustion Resistant CAR-T Cell (c-Jun Overexpression)

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

CAR-expressing T cells demonstrate impressive response rates hematological malignancies, but mediate limited anti-tumor efficacy in solid tumors. The T cell exhaustion-mediated dysfunction is an important barrier to progress, which raises the prospect that engineering exhaustion-resistant CAR-T cells could improve clinical outcomes.

Benefiting from advanced technology and years of experience, Creative Biolabs is gaining even greater success in developing innovative next-generation CAR-T products. We are proud to present a model CAR system - c-Jun overexpression-mediated T cell resistant to exhaustion, which is most likely to exert maximum anti-tumor efficacy in solid tumors, thereby addressing a major obstacle to this emerging therapeutic class.

c-Jun CAR Design

A theoretical basis for exhaustion in human T cells expressing CAR receptors is that because of an imbalance between activating and immunoregulatory AP-1-IRF complexes by inducing overexpression of c-Jun - an AP-1 family transcription factor associated with productive T cell activation. A paper published in the journal Nature in December 2019 confirmed this hypothesis.

To study the biology of exhaustion in T cells, the authors used a model system that induces fatigue by expressing the tone signal CAR. They designed a bicistronic CAR vector incorporating a JUN-P2A region, 14g2a-E101K scFv, which has shown enhanced amplification potential, enhanced functionality, reduced terminal differentiation and improvement antitumor efficacy in multiple in vivo models.

Schematic representation of c-Jun overexpressed CAR vector.

Fig.1 Schematic representation of c-Jun overexpressed CAR vector.

One-stop CAR Development Services

With state-of-art CAR development platforms and advanced technologies, Creative Biolabs is capable of offering CAR-T-cell development services. For the regular or custom CAR backbone construction, please refer to our related services: CAR Design & Construction. To further assess your c-Jun CAR biological efficacy (e.g., cytokine production, tumor killing, and CAR-T cell proliferation), our scientists can also provide comprehensive downstream services to complete your whole research. Please click CAR Cell In Vitro Assay Service, CAR-T Preclinical In Vivo Assay for more details.

CAR Biomarker indentification & selection High affinity scFv generation CAR design & construction Virus packaging & CAR transfection CAR in vitro assay CAR Pre-clinical in vivo assay CAR clinical trial

Features of our Services

Highly efficient
One-stop pipeline
Skillful scientific team
Best after-sale service

For more detailed information, please feel free to contact us or directly sent us an inquiry.

Reference

Rachel C. Lynn.; et al. c-Jun overexpression in CAR-T cells induces exhaustion resistance. Nature, 2019. Volume 576, pages 293-300.

Key Updates

NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER

NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION

NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY

NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION